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Objective: rhuMAb 2C4 (pertuzumab, RO4368451), a human epidermal growth factor recep-
tor-2 (HER2) targeted antibody that binds to an epitope distinct from trastuzumab, blocks
ligand-associated heterodimerization of HER2 with other HER receptor family members. This
study evaluated the toxicity, pharmacokinetics and anti-tumor activities of pertuzumab in
Japanese patients with solid tumors.
Methods: Patients with solid tumors refractory to standard therapy were administered pertu-
zumab 5, 10, 15, 20 and 25 mg/kg intravenously once every 3 weeks. Grade 3 toxicities were
considered as dose limiting. The maximum tolerated dose (MTD) was a dose at which two
out of six patients had Grade 3 toxicities.
Results: Eighteen patients, aged 38–66 (median 57) years, with solid tumors were enrolled
and a total of 32 cycles of pertuzumab were administered. Toxicities were generally accepta-
ble. Grade 3 elevation of gamma-glutamyl transpeptidase was observed in one patient at
25 mg/kg and was considered to be dose limiting. MTD was not reached up to a dose level of
25 mg/kg. The serum concentration of pertuzumab declined slowly (terminal half-life is
approximately 3 weeks). The AUC proportionally increased over the dose range tested. There
was limited evidence of activity (stable disease 2; progressive disease 13; and not evaluable
3); however, tumor shrinkage and tumor marker decrease were observed in an ovarian
cancer and a non-small-cell lung cancer patient, respectively.
Conclusions: Pertuzumab is well tolerated up to 25 mg/kg. Although objective tumor
response was not observed, it is worth evaluating as a ﬂat dose and in combination with
other cytotoxics and molecular-targeted agents.
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INTRODUCTION
The human epidermal growth factor receptor (HER) family
consists of four tyrosine kinase receptors: HER1/ErbB-1
[epidermal growth factor receptor (EGFR)], HER2/ErbB-2/
Neu, HER3/ErbB-3 and HER4/ErbB-4 (1). These receptors
are highly expressed in many solid tumor types, including
lung (2), breast (3), ovarian (4), colorectal (5) and prostate
(6). They also play an important role in the proliferation,
differentiation, motility, adhesion, protection from apoptosis
and transformation of tumor cells (1,7,8). Receptor
dimerization is essential for HER pathway activation,
leading to phosphorylation and downstream signal transduc-
tion (1). Unlike HER1, HER3 and HER4, HER2 is con-
sidered to be an orphan receptor: no direct ligand for HER2
has been discovered. HER2 assumes an open conformation,
with its dimerization domain permanently exposed for inter-
action with other ligand-activated HER receptors (9). HER2
is the preferred partner for dimer formation, and pre-clinical
studies have demonstrated that HER2-containing heterodi-
mers are the most mitogenic and have the highest transform-
ation potential of all the HER complexes (1,10,11).
Pertuzumab (rhuMAb 2C4, RO4368451) is a recombinant,
humanized monoclonal antibody that targets an epitope
within the HER2 dimerization domain (12,13). Pertuzumab
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doi:10.1093/jjco/hyp006inhibits the formation of the HER2 heterodimer, independent
of HER2 expression levels, and its binding site does not
overlap with the epitope on HER2 that is recognized by tras-
tuzumab (Herceptin) (14,15). Pertuzumab has demonstrated
growth inhibition in ovarian, lung, breast and prostate tumor
cells without HER2 overexpression (15). In the initial US
P h a s eIs t u d y ,t h ed o s eo fp e r t u z u m a bw a se s c a l a t e df r o m
0.5 to 15 mg/kg. The majority of adverse events were of
Grades 1–2 severity and included asthenia, vomiting,
nausea, abdominal pain, rash, diarrhea, pain and anemia. A
Grade 3 gastrointestinal hemorrhage was observed at the
15 mg/kg dose level and this was determined as a dose-
limiting toxicity (DLT); however, the maximum tolerated
dose (MTD) was not reached up to the dose level of 15 mg/
kg. Two out of 21 patients, one with ovarian cancer and the
other with pancreatic islet cell carcinoma, achieved a partial
response (16).
In light of these promising pre-clinical and clinical ﬁnd-
ings, we conducted a Phase I study of pertuzumab in
Japanese patients with solid tumors. The objectives of this
study were to determine the toxicity, pharmacokinetics and
anti-tumor activities of pertuzumab.
PATIENTS AND METHODS
PATIENT ELIGIBILITY
Patients were eligible if they had histologically or cytologi-
cally conﬁrmed malignant solid tumors that were resistant to
standard therapies, or for which there was no effective treat-
ment. HER2 status was not used in the selection process,
except for those patients with breast cancer. Eligibility cri-
teria were: age 20–74 years; Eastern Cooperative Oncology
Group (ECOG) performance status (PS) 0 or 1; life expect-
ancy .12 weeks; no previous chemotherapy, radiation
therapy or surgery within 4 weeks before treatment with per-
tuzumab (6 weeks for previous treatment with nitrosoureas
or mitomycin); adequate bone marrow (absolute neutrophil
count 1500/mm
3, platelet count 75 000/mm
3 and hemo-
globin level 9.0 g/dl), hepatic [serum total bilirubin
1.5 mg/dl, aspartate amino transferase (AST) 80 IU/l,
alanine amine transferase (ALT) 80 IU/l and alkaline phos-
phatase (ALP) 1400 IU/l], renal (serum creatinine
1.3 mg/dl), coagulation [prothrombin time international
normalized ratio (PT-INR) ,1.3, activated partial thrombo-
plastin time (APTT) ,60 s], pulmonary [arterial oxygen
pressure (PaO2) 70 torr], and cardiac [left ventricular ejec-
tion fraction (LVEF) 50% by echocardiography] functions.
Exclusion criteria included: pregnancy or lactation; sympto-
matic brain metastasis; HER2-positive breast cancer by ﬂuor-
escence in situ hybridization; previous treatment with
antibody agents for HER receptors; a history of hypersensi-
tivity reactions to any drug; pleural effusion and ascites that
required drainage; cumulative doxorubicin dose of
360 mg/m
2 given prior to study; hepatitis B or C or HIV;
and serious pre-existing medical conditions such as
uncontrolled infections, hypertension, hypercalcemia, dia-
betes, severe heart disease or psychogenic disorders.
Written informed consent was obtained from all patients.
The study was approved by the institutional review board at
the National Cancer Center, and conducted in accordance
with Japanese Good Clinical Practice (GCP) guidelines.
DRUG ADMINISTRATION AND DOSE ESCALATION PROCEDURE
Pertuzumab (rhuMAb 2C4, RO4368451) was supplied by
Chugai Pharmaceutical Co. Ltd (Tokyo, Japan). Each 10 ml
vial contained approximately 175 mg pertuzumab formulated
in 10 mmol/l L-histidine (pH 6.0), 240 mmol/l sucrose and
0.02% polysorbate 20. Pertuzumab was diluted in 250 ml
saline immediately prior to administration. The calculated
dose was administered by a 90 min intravenous infusion at
the initial cycle of treatment, and repeated every 3 weeks.
No prophylactic pre-medication to reduce hypersensitivity
reaction was given. If no hypersensitivity reaction (related to
pertuzumab administration) was observed, administration
was shortened to a 30 min infusion after the second treat-
ment cycle.
The starting dose was 5 mg/kg, with subsequent dose
escalations to 10, 15, 20 and 25 mg/kg. The upper dose of
25 mg/kg was set based on the serum trough level estimation
of efﬁcacy in pre-clinical models (25 mg/ml) with the aim of
exploring the safety range in Japanese patients considering
the differences in body weight between patients from
western countries and those from Japan. At least three
patients were entered at each dose level. Three additional
patients were entered at the same dose, if a DLT was
observed in one of the initial three patients. The MTD was
deﬁned as the dose level at which two of three to six patients
experienced DLT. DLT was deﬁned as: Grade 4 hematologi-
cal toxicities; Grade 3 or 4 non-hematological toxicities
except for AST/ALT and serum creatinine elevations; AST/
ALT elevations .150 IU/l; or serum creatinine elevation
.2.0 mg/dl.
PRE-TREATMENT ASSESSMENT AND FOLLOW-UP STUDIES
Complete clinical assessments, including physical examin-
ation, ECOG PS, blood pressure, weight, chest X-ray, ECG,
echocardiography and routine laboratory tests, were per-
formed for all patients before study entry and prior to each
treatment cycle. Routine laboratory tests included complete
blood count and differential testing of electrolytes, urea
nitrogen, serum creatinine, serum total protein, serum
albumin, glucose, total bilirubin, AST, ALT, ALP, lactic
dehydrogenase, gamma-glutamyl transferase, PaO2, adequate
tumor markers, PT-INR, APTT and urinalysis. With the
exception of PaO2 and tumor markers, these laboratory tests
were repeated on Days 1, 8, 22, 29 and 42, and then every
3w e e k s .P a O 2 was assessed on an as needed basis. Tumor
markers were assessed on alternate treatment cycles (cycles
Jpn J Clin Oncol 2009;39(4) 2611 and 3). Anti-pertuzumab antibody was assessed before
each treatment cycle.
Toxicities were evaluated according to the National
Cancer Institute Common Toxicity Criteria (NCI-CTC)
version 2.0. Tumor responses were evaluated according to
Response Evaluation Criteria in Solid Tumors (RECIST) cri-
teria (17).
PHARMACOKINETICS
Pharmacokinetic evaluation was performed in all patients.
Venous blood samples (5 ml) were taken and immediately
centrifuged at 1500 rpm for 10 min. Serum was aliquoted
a n ds t o r e da t2708C or less in polyethylene tubes until
analysis. Pharmacokinetic sampling points in the initial treat-
ment cycle were before infusion, at the end of infusion, after
1.5, 4 and 8 h, and at 8, 15 and 22 days after completion of
infusion. In the second treatment cycle, sampling points
were before infusion, at the end of infusion, at 4 and 8 h,
and at 8 and 22 days. For the third cycle, pharmacokinetic
samples were taken before infusion, at the end of infusion,
and 8 and 22 days after treatment.
The concentration of pertuzumab in serum was measured
by receptor-binding enzyme-linked immunosorbent assay
using p185
HER2 extracellular domain to capture pertuzumab.
Bound pertuzumab was detected with mouse anti-human
Fc-horseradish peroxidase (Jackson ImmunoResearch
Laboratories Inc., West Grove, PA, USA), and tetramethyl
benzidine (KPI Inc., Gaithersburg, MD, USA) was used as
the substrate for color development to quantify serum pertu-
zumab against a known standard curve. The minimum quan-
tiﬁable concentration was 0.025 mg/ml.
Analyzed pharmacokinetic parameters included the
maximum plasma drug concentration (Cmax), area under the
plasma drug concentration–time curve (AUC), distribution
volume at steady state (Vdss), terminal half-life, mean resi-
dence time (MRT) and clearance (CL). These data were ana-
lyzed by two-compartmental method analysis using the
WinNonlin software program version 4.1 (Pharsight
Corporation, CA, USA).
RESULTS
PATIENT CHARACTERISTICS
Eighteen patients (11 males and 7 females; ECOG PS 0 or
1) were entered in the study. Patient characteristics are
shown in Table 1. Median age and body weight were 57
(range 38–66) years and 57.9 (42.9–73.5) kg, respectively.
Non-small-cell lung cancer (NSCLC) was the predominant
tumor type. Thirteen patients had received surgical resection
for primary tumors, 18 had received prior chemotherapy and
8h a d4 prior treatment regimens. A total of 32 cycles of
pertuzumab were administered, and the median number of
cycles administered per patient was 2 (range 1–4). All 18
patients were included in the toxicity evaluation and 15
patients met the RECIST criteria. Three patients were not
evaluable for efﬁcacy because they did not meet RECIST
criteria for adequate measurable lesions.
SAFETY AND TOLERABILITY
The main toxicities seen in all cycles of treatment are
shown in Table 2. The majority of toxicities were mild
(Grades 1–2) in severity, and diarrhea, rash, brain natriuretic
peptide (BNP) increase and lymphopenia were the most
frequent toxicities seen.
Diarrhea was observed in 11 (61.1%) of 18 patients; 10 of
these were deﬁned as Grade 1, and 1 was Grade 2. The onset
of diarrhea was within 1 week of treatment and resolved on
treatment with a Lactobacillus preparation. No watery diar-
rhea was observed and treatment with loperamide was not
required.
Rash was experienced by 9 (50%) of 18 patients, 6 of
which were deﬁned as Grade 1 and 3 as Grade 2, and mostly
consisted of acne and seborrhea. The onset of these skin
toxicities generally occurred within 7–14 days of the initial
treatment cycle, persisting for 1–2 weeks and almost asymp-
tomatic with no medication required.
BNP increase and lymphopenia were observed in nine
(50%) and seven (38.9%) patients, respectively. The largest
elevation of BNP was 119.5 pg/ml in the 20 mg/kg cohort,
but this patient was asymptomatic. No cardiac dysfunction
(assessed by troponin-T, ECG and echocardiography)
Table 1. Patient characteristics
Characteristics No. of patients
Total no. of patients 18
Male/female 11/7
ECOG performance status
05
11 3
Tumor type
NSCLC 7
Rectum 3
Stomach 2
Ovary 2
Breast 1
Esophagus 1
Germ cell 1
Primary unknown 1
Prior treatment
Surgery 13
Radiotherapy 6
Chemotherapy 18
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small-cell lung
cancer.
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also asymptomatic, and the severity appeared to be
dose-related.
Hypersensitivity reactions were observed in two patients
immediately following pertuzumab administration: one
experienced Grade 1 fever and the other had Grade 2 fever.
Both resolved without medication. No other hypersensitivity
symptoms, such as dyspnea, bronchospasm, hypotension or
tachycardia, were observed.
One patient at the 25 mg/kg dose level had a Grade 3
gamma-glutamyl transpeptidase (gamma-GTP) increase.
This patient was a 57-year-old man, with ECOG PS 1, who
was diagnosed with advanced gastric cancer with multiple
liver metastases. The Grade 3 gamma-GTP increase was
observed on the third day of pertuzumab treatment, but it
was asymptomatic and resolved without medication. It was
considered to be a DLT according to the DLT deﬁnition.
Up to the 25 mg/kg dose level, one DLT (Grade 3
gamma-GTP increase at a dose of 25 mg/kg) was observed.
Other toxicities were considered acceptable. Therefore, the
MTD was not reached, and the acceptable tolerability of per-
tuzumab doses up to 25 mg/kg was conﬁrmed.
ANTI-TUMOR ACTIVITY
Fifteen of 18 patients were evaluable for anti-tumor
response. Two patients had stable disease (one rectal cancer
and one NSCLC), and 13 had progressive disease. There was
limited evidence of anti-tumor activity in this study; there-
fore, a relationship between pertuzumab dose and anti-tumor
response could not be determined.
PHARMACOKINETICS
Serum sampling for pharmacokinetic analysis was per-
formed in all 18 patients in the initial cycle of treatment.
In subsequent cycles, samples from only 9 of 18 patients
were available for pharmacokinetic analysis; the other 9
patients were withdrawn due to disease progression. The
pharmacokinetic proﬁle of pertuzumab is summarized in
Table 3, and trough concentrations of subsequent cycles
are summarized in Table 4. Also, the mean serum concen-
tration–time proﬁles of pertuzumab are illustrated in
Fig. 1.
The concentration–time proﬁle of pertuzumab was bipha-
sic, with mean initial half-life and terminal half-life of
11.6 h and 17.3 days at the 25 mg/kg dose level, respect-
ively. Vdss and CL showed moderate inter-individual varia-
bility and the mean+SD values (CV%) for Vdss and CL
were 92.4+15.2 (16.5 CV%) ml/kg and 4.30+1.72 (40.1
CV%) ml/day/kg, respectively. At doses of 5–25 mg/kg, CL,
Vdss, the distribution volume of the central compartment (Vc)
and the terminal half-life did not change with dose. The
peak serum concentration (Cmax) and the AUC increased
Table 2. Major toxicities in all cycles
Pertuzumab dose (mg/kg) 5 10 15 20 25 Total %
No. of patients 33336
NCI-CTC grade 1, 2 31 , 231 , 231 , 231 , 23
Diarrhea 2 0 3 0 3 0 2 0 1 0 11 61.1
Rash 3 0 2 0 1 0 0 0 3 0 9 50.0
BNP increase 2 0 0 0 2 0 1 0 4 0 9 50.0
Lymphopenia 1 0 0 0 1 1 2 0 1 1 7 38.9
Anemia 1 0 1 0 0 0 1 0 2 0 5 27.8
Leukocytosis 2 0 1 0 1 0 1 0 0 0 5 27.8
Hyperglycemia 0 0 2 0 2 0 0 0 1 0 5 27.8
Neutropenia 2 0 1 0 1 0 0 0 0 0 4 22.2
Leukopenia 1 0 0 0 0 0 2 0 1 0 4 22.2
Nausea 2 0 0 0 0 0 0 0 1 0 3 16.7
Stomatitis 0 0 0 0 1 0 0 0 2 0 3 16.7
Asthenia 1 0 0 0 1 0 1 0 0 0 3 16.7
Gamma-GTP increase 0 0 0 0 0 0 0 0 1 1
a 2 11.1
HSR 0 0 0 0 0 0 0 0 2 0 2 11.1
BNP, brain natriuretic peptide; Gamma-GTP, gamma-glutamyl transpeptidase; HSR, hypersensitivity reaction; NCI-CTC, National Cancer Institute Common
Toxicity Criteria.
aDose-limiting toxicity.
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r ¼ 0.808, respectively), suggesting linear pharmacokinetics
within the dose range in this study.
DISCUSSION
Pertuzumab is a humanized monoclonal antibody that inhi-
bits dimerization of HER2 with other ligand-activated HER
kinases. At the start of this study, the pertuzumab study with
aﬂ a td o s e( i . e .u n a d j u s t e db yb o d yw e i g h t )w a sa l s oi n
preliminary stages in western countries. Its planned higher
dose (1050 mg/person) was based on the highest pertuzumab
dose in the US Phase I study (15 mg/kg) and a median body
weight of approximately 70 kg. As the body weight of
Japanese patients was expected to be lower than US patients,
it was thought that this study needed to determine the safety
range of pertuzumab doses of more than 15 mg/kg in this
population. Although one DLT was observed at the 25 mg/
kg dose level, pertuzumab was generally well tolerated and
the MTD of pertuzumab was not reached up to a dose level
of 25 mg/kg.
The most frequent toxicities observed were diarrhea, rash,
BNP increase and lymphopenia. The most frequent adverse
event was diarrhea (61.1%), which was generally consistent
with ﬁndings from the initial Phase I study in the USA (43%)
(16), though higher than that observed with other humanized
antibodies (trastuzumab, bevacizumab and cetuximab: ,10%)
(18–23). However, severity was generally mild (10 of 11 cases
were Grade 1) and intensive supportive treatment such as loper-
amide was not required. The precise mechanism of the diarrhea
observed has not been determined, but it was considered that
pertuzumab was tolerable in Japanese patients.
Rash was experienced by 50% of patients, mostly consist-
ing of acne and seborrhea. The proﬁle of rash was similar to
that seen in the US study (16). As pertuzumab inhibits het-
erodimerization of HER1/HER2, this rash was considered as
Table 4. Trough concentration ratio of subsequent cycles
Dose (mg/kg) No. of cycles No. of patients Mean Standard deviation CV (%) Median Min Max
5 2 2 1.43 0.610 42.6 1.43 1.00 1.86
3 2 2.29 0.0427 1.9 2.29 2.26 2.32
10 2 1 1.72 — — 1.72 1.72 1.72
15 2 1 1.43 — — 1.43 1.43 1.43
20 2 1 1.76 — — 1.76 1.76 1.76
25 2 4 1.88 0.0805 4.3 1.86 1.81 2.00
3 1 2.31 — — 2.31 2.31 2.31
CV, coefﬁcient of variation.
Figure 1. Mean serum concentration–time proﬁles of pertuzumab.
Table 3. Pharmacokinetic parameters
Dose (mg/kg) No. of patients Cmax (mg/ml) AUC (day*mg/ml) CL (ml/day/kg) Vc (ml/kg) Vdss (ml/kg) MRT (days) t1/2 initial (h) t1/2 terminal (days)
5 3 105+14.2 928+162 5.51+1.03 46.0+6.54 88.5+14.5 16.3+2.89 7.17+4.47 11.5+1.95
10 3 178+31.1 2190+813 4.95+1.60 56.0+9.12 95.1+15.3 20.0+3.83 13.6+7.89 14.3+2.66
15 3 314+65.1 4220+2090 4.24+2.17 48.6+11.1 96.3+32.5 24.7+7.32 26.5+10.7 18.2+5.17
20 3 334+62.4 3870+576 5.25+0.848 57.7+8.22 85.6+6.70 16.7+3.59 5.02+5.22 11.7+2.61
25 6 495+91.8 6490+2090 4.30+1.72 50.4+12.7 92.4+15.2 24.2+9.37 11.6+9.81 17.3+6.97
Values are mean+SD. AUC, area under plasma drug concentration–time curve; CL, clearance; Cmax, maximum plasma drug concentration; MRT, mean
residence time; t1/2, half-life; Vc, distribution volume of the central compartment; Vdss, distribution volume at steady state.
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mild in severity and it was thought that pertuzumab-related
rash was milder than the reported skin disorders due to
EGFR inhibition with cetuximab (22–24).
Hypersensitivity reactions were observed in two (11.1%)
patients. These reactions were transient fever and headache
and resolved immediately without medication. Furthermore,
no anti-pertuzumab antibody production was observed.
Therefore, the administration of pertuzumab could be con-
sidered as safe as other humanized monoclonal antibodies,
such as bevacizumab and cetuximab.
Following prior experience with trastuzumab (25), cardio-
toxicity was closely monitored throughout this study. A BNP
increase was observed in 50% of patients; however, no clini-
cally signiﬁcant cardiotoxicity or other laboratory abnormal-
ities, such as troponin-T increase and LVEF decrease, were
observed.
A DLT (Grade 3 gamma-GTP increase) was observed in
one patient at the 25 mg/kg dose level. This resolved without
medication. As pertuzumab is not metabolized by the liver,
the causality could not be considered as deﬁnite. Routine
measurement of gamma-GTP levels was not included in the
initial study design, so the frequency of such increases is
unknown. Routine assessment of gamma-GTP levels should
be considered for future studies.
The pharmacokinetic proﬁle of pertuzumab revealed mod-
erate inter-individual variability and linear pharmacokinetics.
The mean terminal half-life at the 25 mg/kg dose level was
17.3 days, and the concentration–time proﬁle was similar to
that of other monoclonal antibodies such as trastuzumab
(25.5 days) and bevacizumab (18.4 days). The observed
pharmacokinetic proﬁle was similar to that seen in the
US Phase I study (16). The variability of pertuzumab
steady-state trough serum concentrations and exposure after
ﬁxed, body-weight-based, or body-surface area (BSA)-based
dosing in cancer patients had previously been examined
(26), and demonstrated the feasibility of administration using
ﬂat dosing in speciﬁc patients such as ovarian or breast
cancer patients.
In this Phase I study, the safe range of pertuzumab dosing
in Japanese patients was determined to be up to 25 mg/kg.
This dose level was higher than that determined in the US
Phase I study (15 mg/kg). However, the median body weight
of enrolled patients in this study was 57.9 kg, compared with
a median body weight of 69.0 kg for patients in the US
study. Considering the results from these studies and the
respective patient body weights, it is thought that this pertu-
zumab dose range may apply for common dose settings such
as a ﬂat dose in further studies.
In conclusion, the MTD of pertuzumab was not reached
up to a dose of 25 mg/kg and acceptable tolerability was
conﬁrmed. Although an objective anti-tumor effect was not
observed in this study, the proﬁle of pertuzumab is unique
and encouraging, and further investigation with ﬂat doses
and in combination with other cytotoxic or molecular-
targeted drugs for various tumor types is warranted.
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